PDF(Pubmed)
Abstract：
CAR T-cell therapy is a promising immunotherapy, providing successful results for cancer patients who are unresponsive to standard and traditional therapeutic approaches. However, there are limiting factors which create a hurdle in the therapy performing its role optimally. CAR T cells get exhausted, produce active antitumor responses, and might even produce toxic reactions. Specifically, in the case of solid tumors, chimeric antigen receptor T (CAR-T) cells fail to produce the desired outcomes. Then, the need to use supplementary agents such as immune system modifying immunomodulatory agents comes into play. A series of the literature was studied to evaluate the role of immunomodulators including a phytochemical, Food and Drug Administration (FDA)-approved targeted drugs, and ILs in support of their achievements in boosting the efficiency of CAR-T cell therapy. Some of the most promising out of them are reported in this article. It is expected that by using the right combinations of immunotherapy, immunomodulators, and traditional cancer treatments, the best possible cancer defying results may be produced in the future.
摘要：
CAR-T细胞疗法是一种很有前途的免疫疗法,为对标准和传统治疗方法无反应的癌症患者提供成功的结果。然而,有一些限制因素会在治疗中产生障碍，使其发挥最佳作用。CAR-T细胞耗尽,产生积极的抗肿瘤反应，甚至可能产生毒性反应。具体来说,在实体瘤的情况下，嵌合抗原受体T（CAR-T）细胞无法产生所需的结果。然后，需要使用补充剂，如免疫系统修饰免疫调节剂开始发挥作用。研究了一系列文献来评估免疫调节剂的作用，包括植物化学物质，美国食品和药物管理局（FDA）批准的靶向药物，和IL支持他们在提高CAR-T细胞治疗效率方面的成就。本文报道了其中一些最有前途的。预计通过使用正确的免疫疗法组合，免疫调节剂,和传统的癌症治疗方法，最好的癌症抵抗结果可能会在未来产生。
